Core Insights - IMUNON, Inc. announced positive results from its Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for advanced ovarian cancer, showing significant improvements in overall and progression-free survival [1][3][4] - The company has initiated the pivotal Phase 3 OVATION 3 Study following alignment with the FDA, focusing on newly diagnosed advanced ovarian cancer patients [2][5] Group 1: Study Results - The Phase 2 OVATION 2 Study demonstrated a median increase in overall survival (OS) of 13 months for patients treated with IMNN-001 plus standard of care (SoC) compared to SoC alone (46 months vs. 33 months) [3][8] - Patients receiving IMNN-001 in conjunction with PARP inhibitors showed a median OS not yet reached after more than five years, compared to 37 months in the control group, indicating a hazard ratio of 0.38 [3][8] - The study also reported a median 3-month increase in progression-free survival (PFS) for the intent-to-treat population (14.9 months vs. 11.9 months) with a hazard ratio of 0.79 [3][8] Group 2: Treatment Details - IMNN-001 is administered intraperitoneally at a dose of 100 mg/m weekly, combined with neoadjuvant and adjuvant chemotherapy [6][7] - The study enrolled 112 patients with newly diagnosed advanced epithelial ovarian cancer, randomized 1:1 to evaluate the safety and efficacy of IMNN-001 plus chemotherapy versus standard chemotherapy alone [6][7] Group 3: Future Directions - The Phase 3 OVATION 3 Study will include women with newly diagnosed advanced ovarian cancer (stage IIIC or IV) and will assess overall survival as the primary endpoint [5] - The study will also evaluate secondary endpoints such as surgical response score and time to second-line treatment, with a focus on patients with homologous recombination deficiency (HRD+) [5] Group 4: Company Overview - IMUNON is a clinical-stage biotechnology company developing innovative treatments using its proprietary TheraPlas technology platform, which focuses on gene-based delivery of cytokines for cancer treatment [10][11] - The company aims to leverage its technology to provide effective and durable responses for patients with difficult-to-treat conditions, including advanced ovarian cancer [10][11]

Core Insights - Super League has sold its Minecraft property InPVP to Mineville LLC in an all-cash transaction, aimed at streamlining operations and reducing costs while focusing on playable media and content solutions for global brands [1][4] - The acquisition allows Mineville to expand into the Minecraft Bedrock ecosystem, which encompasses a majority of active Minecraft players [2] - Super League will become Mineville's exclusive partner for brand partnerships and advertising sales, increasing audience reach to 8.1 million monthly active Minecraft users [3] Company Overview - Super League is a leader in engaging audiences through playable media, providing global brands with ads, content, and experiences that are interactive and memorable within mobile games and immersive gaming platforms [5] - The company utilizes proprietary technology and a network of native creators to help brands stand out and drive consumer loyalty [5]

Summary of Jasper Therapeutics (JSPR) Conference Call Company Overview - Jasper Therapeutics focuses on mast cell-mediated diseases, with its lead asset being briquelimab, a monoclonal antibody targeting c-KIT on mast cells [2][3] Core Points and Arguments Mechanism of Action - Briquelimab targets c-KIT, which is crucial for mast cell survival. Inhibition leads to mast cell apoptosis, making it a clean mechanism for treating related diseases [3][4][5] Clinical Trials and Data - The BEACON study is a Phase 1/2 trial exploring optimal dosing of briquelimab in chronic spontaneous urticaria (CSU) [6] - Initial data showed a rapid onset of clinical relief, with complete responses ranging from 50% to 100% at the 240 mg dose level, durable for eight weeks [10][12] - The study tested doses from 10 mg to 240 mg, with a half-life of approximately nine days for briquelimab [7][9] Safety Profile - The safety profile of briquelimab appears favorable, with no unexpected adverse events reported. Most c-KIT related adverse events were mild and transient [21][24] - Neutropenia concerns were addressed, indicating that stem cells remain viable despite c-KIT inhibition [22][24] Future Data and Expectations - Upcoming data from the BEACON study is expected in mid-2025, which will help differentiate briquelimab from competitors like Barzolumab [25][26] - The company plans to initiate a Phase 2b adaptive clinical trial by the end of 2025 [27] Competitive Landscape - The approval of Dupixent is seen as beneficial for educating dermatologists about biologics in CSU, but briquelimab and Barzolumab are the only therapies that deplete mast cells [39][40] - Briquelimab is positioned as a potential therapy of choice in the CSU setting due to its unique mechanism [41] Broader Pipeline - Jasper Therapeutics is also exploring briquelimab for mild to moderate asthma, with data expected in the second half of 2025 [42][43] - The company is considering additional indications, targeting diseases that are mast cell-mediated [42] Important but Overlooked Content - The BEACON study's small sample size may affect the interpretation of data, particularly regarding the complete response rates [12][18] - The potential for misdiagnosis in patients with CSU was highlighted, indicating the need for careful patient selection [19] This summary encapsulates the key points discussed during the conference call, providing insights into Jasper Therapeutics' current status, future plans, and competitive positioning in the market.

Yield of Fumed Silica Material Exceeds Expectations in Latest Pilot RunsMONTREAL, May 21, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, announces today further to its news release ...

一、跨平台发布的底层逻辑：流量争夺战 很多创作者都纠结：辛辛苦苦拍的原创视频，到底能不能发到不同平台？其实这个问题背后，藏着自媒体行业最核心的流量密码——谁能在更多平台获取用 户注意力，谁就能掌握主动权。 2.算法推荐机制：重复内容在不同平台可能触发限流（建议修改封面、标题、标签） 3.用户画像冲突：抖音用户偏娱乐化，B站用户注重深度，需调整视频剪辑节奏 二、多平台运营的实战技巧（附解决方案） _技巧1：内容微调法则_ 把1条视频变成10条素材的秘诀： 竖版视频截取高潮片段发抖音 横屏完整版发B站/西瓜视频 拆解关键知识点做成图文发小红书 从法律层面看，只要视频是100%原创内容（无侵权素材、无搬运痕迹），版权完全属于创作者，理论上可以在所有平台发布。但实际操作中，有3个关键点 需要注意： 1.平台规则差异：例如某平台要求首发或独家时（如部分中视频计划），发布其他平台可能影响收益 搭配花絮镜头发视频号 _技巧2：账号矩阵布局_ 某旅行博主案例： 抖音：15秒风景混剪（挂车卖旅游套餐） 视频号：30秒人文故事（引导私域咨询） 小红书：图文攻略（植入酒店合作） 西瓜视频：5分钟深度游记（赚播放收益） 三、避坑指南 ...

Company Overview - Integral Ad Science (IAS) is a leading global media measurement and optimization platform that provides actionable data to enhance results for advertisers, publishers, and media platforms [2] - The company's software ensures that advertisements are viewed by real people in safe environments, improving return on ad spend for advertisers and yield for publishers [2] - IAS aims to be the global benchmark for trust and transparency in digital media quality [2] Upcoming Events - Lisa Utzschneider, CEO of IAS, will participate in a fireside chat at the Baird 2025 Global Consumer, Technology & Services Conference on June 5, 2025, at 10:15 a.m. ET [1] - The event will be available via live webcast and archived replay on the IAS investor relations website [1]

Sports.com at Soccerex Amsterdam L to R: Marc Bircham, Tamer Hassan, and Patrick McCreanor, Soccerex FORT WORTH, Texas, May 20, 2025 (GLOBE NEWSWIRE) -- Lottery.com Inc. (NASDAQ: LTRY, LTRYW) (“Lottery.com” or the “Company”), a leading technology company transforming the intersection of gaming, sports and entertainment, is proud to announce its role as Title Sponsor of Soccerex Europe 2025, taking place from May 19–21 at the iconic Johan Cruyff Arena in Amsterdam. As headline sponsor of this globally re ...

Nearly half (47%) of SMBs updated their cybersecurity solutions to further protect their business. More than a third (38%) are actively using AI across multiple business functions, such as data analysis, marketing and customer service. Over 56% of SMBs believe AI can help address issues with employee management and overall employee headcount. 3 in 4 (76%) of SMBs agree that social media positively impacts their business performance. But more than half (54%) of SMBs struggle to keep online content fresh and ...

Core Insights - Harmonic has expanded its partnership with Cignal TV to modernize channel origination, playout, and disaster recovery workflows using its VOS360 Media SaaS platform, which operates on the public cloud [1][2] - The VOS360 Media SaaS enhances Cignal TV's video streaming and broadcast services by providing greater flexibility, agility, and scalability, allowing for the rapid launch of streaming services [2][4] - The solution enables remote switching of local playout operations to the cloud for disaster recovery, ensuring service continuity and high availability for Cignal TV [3][4] Company Overview - Harmonic is a leader in virtualized broadband and video delivery solutions, enabling media companies and service providers to deliver high-quality video streaming and broadcast services globally [6] - The company has revolutionized broadband networking with the first virtualized broadband solution, allowing operators to deploy gigabit internet services more flexibly [6] - Harmonic's innovative cloud and software platforms simplify OTT video delivery and enhance the monetization of live and on-demand content across various screens [6]

Core Insights - The article highlights the presentation of the Tanruprubart Real-World Evidence (RWE) study, demonstrating its benefits over the current standard of care for Guillain-Barré Syndrome (GBS) patients [1][4] - Tanruprubart, a first-in-kind monoclonal antibody, shows significant improvements in muscle strength and overall recovery compared to existing treatments [2][3] Company Overview - Annexon, Inc. is a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases [1][11] - The company’s lead investigational therapy, Tanruprubart, targets C1q to reduce inflammation and nerve damage in GBS [9][11] Clinical Findings - The RWE study matched Tanruprubart-treated patients with those receiving standard care (IVIg or PE), showing a rapid increase in muscle function and sustained recovery [4][8] - By Week 1, patients treated with Tanruprubart exhibited approximately a ten-point improvement in muscle strength compared to those on IVIg or PE [8] - Tanruprubart-treated patients were about three times more likely to achieve a better state of health on the GBS-Disability Scale at Weeks 4, 8, and 26 [8] Treatment Impact - Tanruprubart demonstrated rapid clinical benefits, including improvements in muscle strength, mobility, balance, and coordination, maintained through Week 26 [8] - The treatment allows patients to regain independence and return to daily activities sooner than with standard therapies [8][9] Disease Context - GBS is a rare autoimmune disease affecting at least 150,000 people globally each year, with no FDA-approved therapies currently available [2][10] - The disease can lead to severe weakness and paralysis, often requiring intensive care [2][10]